Molecular property diagnostic suite (MPDS): Development of disease-specific open source web portals for drug discovery$

Abstract Molecular property diagnostic suite (MPDS) is a Galaxy-based open source drug discovery and development platform. MPDS web portals are designed for several diseases, such as tuberculosis, diabetes mellitus, and other metabolic disorders, specifically aimed to evaluate and estimate the drug-likeness of a given molecule. MPDS consists of three modules, namely data libraries, data processing, and data analysis tools which are configured and interconnected to assist drug discovery for specific diseases. The data library module encompasses vast information on chemical space, wherein the MPDS compound library comprises 110.31 million unique molecules generated from public domain databases. Every molecule is assigned with a unique ID and card, which provides complete information for the molecule. Some of the modules in the MPDS are specific to the diseases, while others are non-specific. Importantly, a suitably altered protocol can be effectively generated for another disease-specific MPDS web portal by modifying some of the modules. Thus, the MPDS suite of web portals shows great promise to emerge as disease-specific portals of great value, integrating chemoinformatics, bioinformatics, molecular modelling, and structure- and analogue-based drug discovery approaches.

[1]  Jake Luo,et al.  Big Data Application in Biomedical Research and Health Care: A Literature Review , 2016, Biomedical informatics insights.

[2]  M. Karplus,et al.  Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. , 1993, Journal of medicinal chemistry.

[3]  Marcel L Verdonk,et al.  Detection of secondary binding sites in proteins using fragment screening , 2015, Proceedings of the National Academy of Sciences.

[4]  Maayan Levy,et al.  The Role of the Immune System in Metabolic Health and Disease. , 2017, Cell metabolism.

[5]  P. Kaumaya.  Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. , 2013, Immunotherapy.

[6]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[7]  H. Benyamini,et al.  Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. , 2010, Bioorganic & medicinal chemistry.

[8]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[9]  G. Narahari Sastry,et al.  Sequence, Structure, and Active Site Analyses of p38 MAP Kinase: Exploiting DFG-out Conformation as a Strategy to Design New Type II Leads , 2011, J. Chem. Inf. Model..

[10]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[11]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[12]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[13]  E. Marcotte,et al.  Prioritizing candidate disease genes by network-based boosting of genome-wide association data. , 2011, Genome research.

[14]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[15]  S. Ferro,et al.  Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in anti-retroviral therapy. , 2011, Mini reviews in medicinal chemistry.

[16]  A. Rothe,et al.  Monoclonal antibody treatments for rheumatoid arthritis , 2013, Expert opinion on biological therapy.

[17]  A. Butte,et al.  Leveraging big data to transform target selection and drug discovery , 2016, Clinical pharmacology and therapeutics.

[18]  Bruce T. Volpe,et al.  Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity , 2011, Proceedings of the National Academy of Sciences.

[19]  S. Satyanarayanajois,et al.  Peptides and peptidomimetics as immunomodulators. , 2014, Immunotherapy.

[20]  Vladimir Poroikov,et al.  PASS: prediction of activity spectra for biologically active substances , 2000, Bioinform..

[21]  V. Poroikov,et al.  A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis$ , 2017, SAR and QSAR in environmental research.

[22]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[23]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[24]  A Srinivas Reddy,et al.  Virtual screening in drug discovery -- a computational perspective. , 2007, Current protein & peptide science.

[25]  David B. Searls,et al.  Data integration: challenges for drug discovery , 2005, Nature Reviews Drug Discovery.

[26]  Ameya Gokhale,et al.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58. , 2011, Journal of medicinal chemistry.

[27]  Vladimir Poroikov,et al.  Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource , 2014, Chemistry of Heterocyclic Compounds.

[28]  G. N. Sastry,et al.  Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach. , 2012, Journal of molecular graphics & modelling.

[29]  G. Cline,et al.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.

[30]  S. Lovell,et al.  Protein-protein interaction networks and biology—what's the connection? , 2008, Nature Biotechnology.

[31]  Kayvan Najarian,et al.  Big Data Analytics in Healthcare , 2015, BioMed research international.

[32]  Daniel J. Blankenberg,et al.  Galaxy: A Web‐Based Genome Analysis Tool for Experimentalists , 2010, Current protocols in molecular biology.

[33]  Peter Woollard,et al.  An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations , 2016, PloS one.

[34]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[35]  Viju Raghupathi,et al.  Big data analytics in healthcare: promise and potential , 2014, Health Information Science and Systems.

[36]  P. Kaumaya,et al.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. , 2012, Future oncology.

[37]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[38]  G. N. Sastry,et al.  Dipeptidyl peptidase IV inhibitors: a new paradigm in type 2 diabetes treatment. , 2014, Current drug targets.

[39]  Bridget E. Begg,et al.  A Proteome-Scale Map of the Human Interactome Network , 2014, Cell.

[40]  G Narahari Sastry,et al.  Virtual high throughput screening in new lead identification. , 2011, Combinatorial chemistry & high throughput screening.

[41]  P. Scherer.  From Lipid Storage Compartment to Endocrine Organ , 2006 .

[42]  M. Tsai,et al.  Mast cells and immunoregulation/immunomodulation. , 2011, Advances in experimental medicine and biology.

[43]  W. S. Clark.  The treatment of rheumatoid arthritis. , 1949, The Medical clinics of North America.

[44]  A. Vinayagam,et al.  A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction , 2011, Science Signaling.

[45]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[46]  Yuichi Akasaki,et al.  Sfrp5 Is an Anti-Inflammatory Adipokine That Modulates Metabolic Dysfunction in Obesity , 2010, Science.

[47]  S. H. van der Burg,et al.  Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.

[48]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[49]  William W. Lytton,et al.  Multiscale modeling for drug discovery in brain disease , 2016 .

[50]  Holger Claussen,et al.  Searching Fragment Spaces with Feature Trees , 2009, J. Chem. Inf. Model..

[51]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[52]  Arun Sharma,et al.  Assessing therapeutic potential of molecules: molecular property diagnostic suite for tuberculosis $$(\mathbf{MPDS}^{\mathbf{TB}})$$(MPDSTB) , 2017 .

[53]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[54]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.